Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
暂无分享,去创建一个
N. Petrelli | N. Wolmark | R. Goldberg | M. O’connell | C. Allegra | G. Yothers | L. Fehrenbacher | J. Atkins | L. Colangelo | S. Sharif | T. Seay | S. O'Reilly | L. Chu | C. Azar | S. Lopa | S. O'reilly
[1] R. Fisher. On the Interpretation of χ2 from Contingency Tables, and the Calculation of P , 2010 .
[2] N. Petrelli,et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Norman,et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors , 2009, Nature Medicine.
[4] L. Ellis,et al. Cancer: The nuances of therapy , 2009, Nature.
[5] Sonja Loges,et al. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. , 2009, Cancer cell.
[6] John M L Ebos,et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.
[7] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[8] L. Ellis,et al. VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.
[9] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] N. Wolmark,et al. FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer , 2008, Cancer investigation.
[11] N. Petrelli,et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Saif. Targeted agents for adjuvant therapy of colon cancer. , 2006, Clinical colorectal cancer.
[13] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[14] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[15] Michael R Kosorok,et al. Simultaneous Inferences on the Contrast of Two Hazard Functions with Censored Observations , 2002, Biometrics.
[16] J M Lachin,et al. Statistical considerations in the intent-to-treat principle. , 2000, Controlled clinical trials.
[17] B. Turnbull,et al. Flexible Monitoring: The Error Spending Approach , 1999 .
[18] B. Turnbull,et al. Group Sequential Methods with Applications to Clinical Trials , 1999 .
[19] H. Müller,et al. Hazard rate estimation under random censoring with varying kernels and bandwidths. , 1994, Biometrics.
[20] L. Freedman,et al. Allocation of patients to treatment groups in a controlled clinical study. , 1978, British Journal of Cancer.
[21] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[22] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[23] R. Fisher. On the Interpretation of χ2 from Contingency Tables, and the Calculation of P , 2018, Journal of the Royal Statistical Society Series A (Statistics in Society).
[24] D.,et al. Regression Models and Life-Tables , 2022 .